AIP
IONS icon

Arrowpoint Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Arrowpoint Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$978K Sell
12,338
-26,650
-68% -$2.01M 0.21% 55
2026
Q1 		$2.93M Buy
38,988
+13,971
+56% +$1.1M 2.6% 7
2025
Q4 		$1.98M Buy
25,017
+19,554
+358% +$1.47M 0.29% 29
2025
Q3 		$357K Buy
+5,463
New +$267K 0.36% 57

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Arrowpoint Investment Partners's IONS Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Ionis Pharmaceuticals (IONS) stake by 68% in Q2 2026, selling an estimated $2.01M and leaving 12,338 shares worth $978K. The position accounts for 0.21% of the portfolio, ranked #55.

Arrowpoint Investment Partners first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.93M in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Arrowpoint Investment Partners held 12,338 shares of Ionis Pharmaceuticals worth $978K as of Q2 2026.
  • Arrowpoint Investment Partners sold 26,650 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
  • Ionis Pharmaceuticals made up 0.21% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #55 holding.
  • Arrowpoint Investment Partners first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Arrowpoint Investment Partners's Ionis Pharmaceuticals position peaked at $2.93M in Q1 2026.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.